Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
University of California, San Diego
Merck Sharp & Dohme LLC
Radiation Therapy Oncology Group
Boehringer Ingelheim
Varian, a Siemens Healthineers Company
I-Mab Biopharma US Limited
Incyte Corporation
Dana-Farber Cancer Institute
University of Arkansas
Sanford Health
Massachusetts General Hospital
University of Wisconsin, Madison
Palleon Pharmaceuticals, Inc.
Incyte Corporation
MacroGenics
The University of Texas Health Science Center at San Antonio
Incyte Corporation
GERCOR - Multidisciplinary Oncology Cooperative Group
University of California, San Diego
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Medical College of Wisconsin
University of Colorado, Denver
Hoffmann-La Roche
M.D. Anderson Cancer Center
Alume Biosciences, Inc.
VA Office of Research and Development
M.D. Anderson Cancer Center
GeoVax, Inc.
Wake Forest University Health Sciences
University of Pittsburgh
Intensity Therapeutics, Inc.
City of Hope Medical Center
University of Pittsburgh
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Abramson Cancer Center at Penn Medicine
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
EpicentRx, Inc.
Duke University
University of Arizona
Case Comprehensive Cancer Center
Kura Oncology, Inc.
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center